156 filings
Page 5 of 8
6-K
si5su
31 Aug 21
CureVac’s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
9:13am
6-K
x34j3uhr
30 Aug 21
Current report (foreign)
7:00am
6-K
vrw04b9r0mw f7f8
16 Aug 21
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
7:20am
6-K
sq18ug 8d2uwl3t
16 Aug 21
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
7:18am
6-K
lop7q97yre
30 Jun 21
Current report (foreign)
4:34pm
6-K
7el3j0o
30 Jun 21
Current report (foreign)
7:11am
6-K
vdrkycmh
29 Jun 21
Current report (foreign)
7:04am
6-K
aqqqp
24 Jun 21
CureVac Announces Voting Results of General Meeting
4:16pm
6-K
lx98foosj
23 Jun 21
CureVac Provides Supervisory Board Update
7:47am
6-K
z31r3o
16 Jun 21
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
4:53pm
6-K
iixrgy
4 Jun 21
Current report (foreign)
4:31pm
6-K
5h4 cqm30swf
2 Jun 21
CureVac Appoints Klaus Edvardsen as Chief Development Officer
7:02am
6-K
pndl31qir0tnl7uycfz0
28 May 21
Current report (foreign)
4:31pm
6-K
3zpm1xm
26 May 21
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
7:01am
6-K
b3fx2i tub02sg
13 May 21
Current report (foreign)
7:58am
20-F
evpv83t6xu9
27 Apr 21
Annual report (foreign)
12:00am
6-K
jx2b5juv 8nyvl5mncwa
19 Apr 21
Current report (foreign)
7:00am
6-K
4qihud 39x4u
15 Apr 21
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
8:58am
6-K
c1cr3meh
23 Mar 21
Current report (foreign)
8:00am
6-K
3lc8k6
22 Mar 21
Current report (foreign)
8:26am